Glioma is a type of tumour that starts in the glial cells of the brain or the spine. Since the 1800s, when the disease was first named, survival rates have always been unsatisfactory. Despite great advances in molecular biology and traditional treatment methods, many questions remain to be answered regarding cancer occurrence and the underlying mechanism. Medical doctors remain stymied regarding tumour recurrence and worsening disease after effective treatment. To better understand the relevant questions, in this study, 20 oncogenes and 20 anti-oncogenes were examined in relation to protein structure, from protein structure analysis and dynamic analysis methods to 3D structure analysis and systematic analysis of the structure‒ function relationships of proteins. We hope that these analyses will help promote mechanistic research and the development of new treatments for glioma.

Glioma is a type of tumor that starts in the glial cells of the brain or spine. Since the 1800s, when the disease was first named, its survival rates have always been unsatisfactory. Despite great advances in molecular biology and traditional treatment methods, many questions regarding cancer occurrence and the underlying mechanism remain to be answered. In this study, we assessed the protein structural features of 20 oncogenes and 20 anti‐oncogenes via protein structure and dynamic analysis methods and 3D structural and systematic analyses of the structure–function relationships of proteins. All of these results directly indicate that unfavorable group proteins show more complex structures than favorable group proteins. As the tumor cell microenvironment changes, the balance of oncogene‐related and anti‐oncogene‐related proteins is disrupted, and most of the structures of the two groups of proteins will be disrupted. However, more unfavorable group proteins will maintain and refold to achieve their correct shape faster and perform their functions more quickly than favorable group proteins, and the former thus support cancer development. We hope that these analyses will help promote mechanistic research and the development of new treatments for glioma.